Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders

Author(s): Todd D. Gould, Alyssa M. Picchini, Haim Einat, Husseini K. Manji.

Journal Name: Current Drug Targets

Volume 7 , Issue 11 , 2006


There exists an immediate need to develop novel medications for the treatment of mood disorders such as bipolar disorder and depression. Initial interest in glycogen synthase kinase-3 (GSK-3) as a target for the treatment of mood disorders arose from the finding that the mood stabilizing drug lithium directly inhibited the enzyme. More recent preclinical evidence implicates the modulation of GSK- 3 in either the direct or downstream mechanism of action of many other mood stabilizer and antidepressant medications currently in use. One of the cellular targets of GSK-3, which may mediate some of the effects of lithium and other drugs, is β-catenin, a transcription factor that is rapidly degraded when GSK-3 is active. Recent rodent behavioral data (both genetic and pharmacological) supports GSK-3 representing a therapeutically relevant target of lithium. This includes antidepressant-like behavior in the forced swim test and antimaniclike response to amphetamine following administration of the GSK-3 inhibitor AR-A014418, a findings that is concomitant with an increase in brain β-catenin. The evidence described in this review suggests that regulating GSK-3 may represent a target for novel medications to treat mood disorders.

Keywords: Manic-depressive illness, psychopharmacology, mania, depression, mood stabilizer, antidepressant, valproate

Rights & PermissionsPrintExport

Article Details

Year: 2006
Page: [1399 - 1409]
Pages: 11
DOI: 10.2174/1389450110607011399
Price: $58

Article Metrics

PDF: 8
PRC: 0